Novo Nordisk报告说,Cagrilintide是治疗肥胖症和2型糖尿病的新药,第3阶段取得了积极的成果。 Novo Nordisk reports positive phase 3 results for cagrilintide, a new drug showing promise for treating obesity and type 2 diabetes.

新诺迪斯克公司宣布了新一代氨基林类比物卡格林丁的第三期试验结果,该试验显示了对体重控制和代谢健康的有前途结果. Novo Nordisk has announced positive phase 3 trial results for cagrilintide, a next-generation amylin analog, showing promising outcomes in weight management and metabolic health. 数据支持将该药物推进到专门的临床发展计划中,可能被用于肥胖症和2型糖尿病。 The data support advancing the drug into a dedicated clinical development program, with potential applications in obesity and type 2 diabetes. 这些发现突出了卡格利林丁的疗效和安全性,使其成为一种潜在的新治疗选择. The findings highlight cagrilintide’s efficacy and safety profile, positioning it as a potential new treatment option.